
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Psychiatric Digital Biomarkers Market**

According to Intelli, the U.S. Psychiatric Digital Biomarkers Market size was valued at USD 298.9 Million in 2024 and is projected to reach USD 1,567.78 Million by 2032, growing at a compound annual growth rate (CAGR) of 22.78%, during the forecast period of 2024 to 2032.



Psychiatric digital biomarkers are quantifiable, objective data points collected through digital technologies, such as smartphones, wearables, or other sensor-based devices, that provide insights into mental health conditions and psychiatric disorders. These biomarkers can include metrics like sleep patterns, speech and voice features, typing speed, social media activity, heart rate variability, and geolocation data. By continuously monitoring these parameters, digital biomarkers offer a dynamic and real-time understanding of behavioral and physiological changes associated with disorders like depression, anxiety, bipolar disorder, and schizophrenia. Unlike conventional psychiatric assessments, which typically depend on subjective self-reports, clinician-administered interviews, and sporadic evaluations during clinical visits, digital biomarkers offer a transformative approach by enabling passive, continuous, and scalable monitoring of mental health symptoms in naturalistic, real-world settings. Moreover, the longitudinal nature of digital biomarkers supports the development of personalized treatment plans, as they provide feedback on how patients respond to therapies in real time. By enabling proactive and adaptive mental health care, these tools have the potential to significantly improve outcomes, reduce relapses, and enhance overall patient engagement.

**U.S. Psychiatric Digital Biomarkers Market Definition**

The U.S. psychiatric digital biomarkers market refers to the segment of the healthcare and digital health industry focused on the development, validation, and commercialization of digital technologies that collect and analyze quantifiable behavioral and physiological data to assess, monitor, and predict mental health conditions. The market encompasses various stakeholders, including health tech companies, research institutions, mental health service providers, and pharmaceutical firms that utilize digital biomarkers for clinical trials, diagnostics, treatment personalization, and ongoing patient monitoring.

**U.S. Psychiatric Digital Biomarkers Market Overview**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe U.S. psychiatric digital biomarkers market is being propelled by several key drivers that reflect the evolving landscape of mental health care and digital innovation. One of the primary drivers is the rising prevalence of mental health disorders such as depression, anxiety, and bipolar disorder, which has intensified the demand for more effective, scalable, and objective tools for diagnosis and monitoring. Additionally, growing awareness and acceptance of digital health technologies among both patients and healthcare providers have accelerated the adoption of wearable devices, mobile health apps, and telepsychiatry platforms. Advancements in technologies such as artificial intelligence, machine learning, and data analytics are significantly improving the capability to identify subtle behavioral and physiological changes, facilitating earlier diagnosis and more tailored treatment approaches in mental health care. Additionally, the healthcare system's transition toward value-based models and a stronger focus on outcomes-driven care are encouraging the integration of digital biomarkers to enhance treatment effectiveness and patient involvement. Furthermore, increased investment from both government agencies and private investors in digital health solutions, coupled with the FDA’s evolving regulatory support for digital diagnostics and therapeutics, is creating a more supportive landscape for innovation and market growth.

**U.S. Psychiatric Digital Biomarkers Market Segmentation**

The U.S. psychiatric digital biomarkers market is categorized by type, clinical application, and end user, highlighting the broad spectrum of technologies, medical practices, and key stakeholders driving innovation and adoption across the mental health landscape.

**U.S. Psychiatric Digital Biomarkers Market, By Type**

* **Wearables**
* **Mobile-Based Applications**
* **Sensors**

In the U.S. psychiatric digital biomarkers market, segmentation by type reveals a strong dominance of wearables, which currently hold the largest market share. Mobile-based applications represent the fastest-growing segment, fueled by the widespread penetration of smartphones and increasing consumer engagement with mental health apps that track A close-up of hands holding a tablet and a pen

Description automatically generatedmood, social interaction, speech patterns, and more. Meanwhile, sensors, whether standalone or embedded in other platforms, play a critical role in capturing specific psychiatric indicators, such as skin conductance or movement during sleep.

**U.S. Psychiatric Digital Biomarkers Market, By Clinical Practice**

* **Diagnostic Psychiatric Digital Biomarkers**
* **Monitoring Psychiatric Digital Biomarkers**
* **Predictive and Prognostic Psychiatric Digital Biomarkers**

In terms of clinical application, the U.S. psychiatric digital biomarkers market is predominantly led by diagnostic digital biomarkers, which hold the largest market share. Monitoring digital biomarkers are emerging as the fastest-growing segment, driven by the need for continuous, real-time tracking of patient progress and treatment response. predictive and prognostic biomarkers are gaining traction for their ability to forecast disease trajectories and individual responses to interventions, paving the way for precision psychiatry. Together, these clinical practice segments underscore the growing reliance on digital biomarkers to improve diagnostic accuracy, optimize care delivery, and personalize treatment strategies in the evolving mental health landscape.

**U.S. Psychiatric Digital Biomarkers Market, By End Use**

* **Healthcare Companies**
* **Healthcare Providers**
* **Payers**

The U.S. psychiatric digital biomarkers market, when segmented by end use, is primarily dominated by healthcare companies, which account for the largest market share. These include pharmaceutical firms, biotech companies, and digital health startups that are leveraging digital biomarkers to enhance drug development, optimize clinical trials, and deliver personalized therapeutic solutions. Healthcare providers form the second-largest segment, as psychiatrists, psychologists, and clinical practitioners increasingly adopt digital biomarkers to improve diagnostic precision, monitor treatment efficacy, and engage patients more effectively. Meanwhile, payers, including insurance companies and managed care organizations, are recognizing the value of digital biomarkers in supporting A close-up of hands holding a tablet and a pen

Description automatically generatedoutcomes-based reimbursement models, reducing healthcare costs, and promoting preventive care.

**Key Players**

The “U.S. psychiatric digital biomarkers market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Apple Inc., Clario, VivoSense, Inc., IXICO plc, Sonde Health, Inc., PureTech Health PLC, Biogen Inc., Oura Health, Empatica, Microsoft Healthcare, BrainScope Company, Inc., Neurotrack Technologies, Inc. among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2024, he FDA approved Rejoyn ™, a prescription smartphone app aimed at treating major depressive disorder in adults aged 22 and older.
* In 2024, Akili Interactive received FDA approval for EndeavorOTC ®, an over-the-counter video game-based therapy designed to help improve attention in adults with ADHD.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. psychiatric digital biomarkers market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be A close-up of hands holding a tablet and a pen

Description automatically generatedused to assess the competitive landscape U.S. psychiatric digital biomarkers market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generated

TABLE OF CONTENT

1 **INTRODUCTION OF** **U.S. PSYCHIATRIC DIGITAL BIOMARKERS MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. PSYCHIATRIC DIGITAL BIOMARKERS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. PSYCHIATRIC DIGITAL BIOMARKERS MARKET, BY TYPE**

A close-up of hands holding a tablet and a pen

Description automatically generated5.1 Overview

5.2 Wearables

5.3 Mobile-Based Applications

5.4 Sensors

**6 U.S. PSYCHIATRIC DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE**

6.1 Overview

6.2 Diagnostic Psychiatric Digital Biomarkers

6.3 Monitoring Psychiatric Digital Biomarkers

6.4 Predictive and Prognostic Psychiatric Digital Biomarkers

**7** **U.S. PSYCHIATRIC DIGITAL BIOMARKERS MARKET, BY END USE**

7.1 Overview

7.2 Healthcare Companies

7.3 Healthcare Providers

7.4 Payers

1. **U.S. PSYCHIATRIC DIGITAL BIOMARKERS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

A close-up of hands holding a tablet and a pen

Description automatically generated**9.1 Apple Inc.**

* + 1. Overview
    2. Financial Performance
    3. Product Outlook
    4. Key developments
  1. **Clario**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **VivoSense, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **IXICO plc**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Sonde Health, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. A close-up of hands holding a tablet and a pen

     Description automatically generated **PureTech Health PLC**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Biogen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Oura Health**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Empatica**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Microsoft Healthcare**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. A close-up of hands holding a tablet and a pen

     Description automatically generated**BrainScope Company, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Neurotrack Technologies, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research